ArticleHuman vaccines & immunotherapeutics2021

Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions.

Miwako Kobayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.